RAKESH K. JAIN, PHD

Corporate Board Profile

Tech Score: 0/100

abrdn Healthcare Investors

Filing Date	Source Excerpt
2019-04-15	Dr. Rakesh Jain is the Andrew Werk Cook Professor of Tumor Biology in the Department of Radiation Oncology at Harvard Medical School and the Director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital... He serves on the Governance and Nominating Committee of each Fund... The members of each Fund's Committee are Dr. Jain, Mr. Pohotsky and Ms. Stebbins. Ms. Stebbins is the Chairman of the Committee... The members of each Fund's QLCC are Dr. Jain, Mr. Pohotsky and Mr. Reardon... For the fiscal year ended September 30, 2018... Rakesh K. Jain, PhD... $77,000.

Filing Date

Source Excerpt

2019-04-15

Dr. Rakesh Jain is the Andrew Werk Cook Professor of Tumor Biology in the Department of Radiation Oncology at Harvard Medical School and the Director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital... He serves on the Governance and Nominating Committee of each Fund... The members of each Fund's Committee are Dr. Jain, Mr. Pohotsky and Ms. Stebbins. Ms. Stebbins is the Chairman of the Committee... The members of each Fund's QLCC are Dr. Jain, Mr. Pohotsky and Mr. Reardon... For the fiscal year ended September 30, 2018... Rakesh K. Jain, PhD... $77,000.

abrdn Life Sciences Investors

Filing Date	Source Excerpt
2019-04-15	Dr. Rakesh Jain is the Andrew Werk Cook Professor of Tumor Biology in the Department of Radiation Oncology at Harvard Medical School and the Director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital, providing the Fund with a valuable perspective on emerging life sciences technologies. Dr. Jain co-founded XTuit Pharmaceuticals, Inc. in 2012, where he also served as a board member until 2018. He serves on the Governance and Nominating Committee of the Fund. ... For the fiscal year ended September 30, 2018, the Fund paid an annual fee of $15,000 to its Independent Trustees and the Chairman of the Board receives an additional annual fee of $5,000. Additionally, the Fund paid each Independent Trustee $1,000 for each Board and $750 for each Committee meeting attended in person and $250 for each Board and Committee meeting attended by telephone. The Chairman of each of the Audit Committee, the Valuation Committee and the Governance and Nominating Committee of the Fund received an additional annual fee of $2,000. The following table sets forth information regarding compensation of the Trustees and Executive Officer by the Fund for the fiscal year ended September 30, 2018: Rakesh K. Jain, PhD: $19,625.

Filing Date

Source Excerpt

2019-04-15

Dr. Rakesh Jain is the Andrew Werk Cook Professor of Tumor Biology in the Department of Radiation Oncology at Harvard Medical School and the Director of the Edwin L. Steele Laboratory of Tumor Biology at Massachusetts General Hospital, providing the Fund with a valuable perspective on emerging life sciences technologies. Dr. Jain co-founded XTuit Pharmaceuticals, Inc. in 2012, where he also served as a board member until 2018. He serves on the Governance and Nominating Committee of the Fund. ... For the fiscal year ended September 30, 2018, the Fund paid an annual fee of $15,000 to its Independent Trustees and the Chairman of the Board receives an additional annual fee of $5,000. Additionally, the Fund paid each Independent Trustee $1,000 for each Board and $750 for each Committee meeting attended in person and $250 for each Board and Committee meeting attended by telephone. The Chairman of each of the Audit Committee, the Valuation Committee and the Governance and Nominating Committee of the Fund received an additional annual fee of $2,000. The following table sets forth information regarding compensation of the Trustees and Executive Officer by the Fund for the fiscal year ended September 30, 2018: Rakesh K. Jain, PhD: $19,625.

Data sourced from SEC filings. Last updated: 2026-02-03